|Year : 2012 | Volume
| Issue : 5 | Page : 666-671
Heat stable antimicrobial activity of Burkholderia gladioli OR1 against clinical drug resistant isolates
Pratibha Bharti1, Vivek Anand1, Jagdish Chander2, Inder Pal Singh3, Tej Vir Singh4, Rupinder Tewari1
1 Department of Biotechnology, Panjab University, Chandigarh, India
2 Department of Microbiology, Government Medical College & Hospital, Chandigarh, India
3 Department of Natural Products, National Institute of Pharmaceutical Education & Research, S.A.S. Nagar, Punjab, India
4 Department of Chemistry, Panjab University, Chandigarh, India
|Date of Acceptance||14-Dec-2010|
|Date of Web Publication||29-Jun-2012|
Department of Biotechnology, Panjab University, Chandigarh 160 014
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Background & objectives: Drug resistant microbes are a serious challenge to human health. During the search for novel antibiotics/inhibitors from the agricultural soil, a bacterial colony was found to inhibit the growth of clinical isolates including Staphylococcus (resistant to amikacin, ciprofloxacin, clindamycin, clinafloxacin, erythromycin, gentamicin and methicillin) and Candida (resistant to fluconazole and itraconazole). The culture was identified as Burkholderia gladioli and produced at least five different antimicrobial compounds which were highly stable at high temperature (121 o C) and in the broad pH range (3.0-11.0). We report here the antimicrobial activity of B. gladioli against drug resistant bacterial pathogens.
Methods: The bacterial culture was identified using morphological, biochemical and 16S rRNA gene sequencing techniques. The antimicrobial activity of the identified organism against a range of microbial pathogens was checked by Kirby-Bauer's disc diffusion method. The antimicrobial compounds in the cell free supernatant were chloroform-extracted and separated by thin layer chromatography (TLC).
Results: B. gladioli OR1 exhibited broad spectrum antimicrobial activity against drug resistant clinical isolates belonging to various genera of bacteria (Staphylococcus, Enterobacter, Enterococcus, Acinetobacter and Citrobacter) and a fungus (Candida). Based on TLC profile and bioautography studies, the chloroform extract of B. gladioli OR1 consisted of at least three anti-staphylococcal and two anti-Candida metabolites. The antimicrobial activity was heat stable (121 o C/20 min) as well as pH stable (3.0-11.0).
Interpretation & conclusions: The bacterial soil isolate, B. gladioli OR1 possessed the ability to kill various drug resistant bacteria and a fungus. This organism produced many antimicrobial metabolites which might have the potential to be used as antibiotics in future.
Keywords: Antimicrobial activity - Burkholderia gladioli OR1 - Candida - chloroform extract - Staphylococcus
|How to cite this article:|
Bharti P, Anand V, Chander J, Singh IP, Singh TV, Tewari R. Heat stable antimicrobial activity of Burkholderia gladioli OR1 against clinical drug resistant isolates. Indian J Med Res 2012;135:666-71
|How to cite this URL:|
Bharti P, Anand V, Chander J, Singh IP, Singh TV, Tewari R. Heat stable antimicrobial activity of Burkholderia gladioli OR1 against clinical drug resistant isolates. Indian J Med Res [serial online] 2012 [cited 2021 May 15];135:666-71. Available from: https://www.ijmr.org.in/text.asp?2012/135/5/666/97738
Staphylococcus and Candida are the two major agents causing wide array of microbial diseases, especially in infants and immuno-compromized hosts , . If left untreated, these diseases can be fatal , . Although many antibiotics are available for the treatment of staphylococcal and Candida infections, the choice is becoming limited because of the emergence of antibiotic resistance in the clinical isolates belonging to these genera , . The isolation of multi-drug resistant Staphylococcus and Candida is a frequent observation , . Looking at the alarming situation created by the development of drug resistant pathogens, a concerted effort is being made by the scientists to search for new antimicrobial compounds that can kill or inhibit the growth of such drug resistant microbes.
Antibiotic production is generally considered to be the domain of fungi and actinomycetes. However, a few bacteria have also been reported to produce antibiotics , . During the screening for novel bio-active compounds of microbial origin, a bacterial colony, isolated from rhizospheric soil, subsequently identified as Burkholderia gladioli OR1 exhibited inhibitory properties. Here, we report the antimicrobial activity of B. gladioli against clinical drug resistant bacterial and fungal pathogens of human origin.
| Material & Methods|| |
Culture isolation and identification: This study was conducted in the Department of Biotechnology, Panjab University, Chandigarh, India. A spoonful of agricultural soil, obtained from a village Khuda Lahora, near Chandigarh (India), was suspended in 20 ml sterile distilled water, thoroughly agitated and allowed to stand at room temperature for 10 min. Ten-fold dilutions of the aqueous phase of the soil mixture were made, spread-plated on nutrient agar (NA) plates and incubated at 30 o C for 48 h. One bacterial colony found to inhibit the growth of adjoining microbial colonies, was streaked on a fresh NA plate, incubated at 30 o C for 24 h and stored at 4 o C. The isolated bacterial culture was identified based on morphological  , biochemical  and 16S rRNA gene sequencing data  .
Extraction of antimicrobial compounds from B. gladioli OR1: B. gladioli OR1 (1.0% inoculum) was grown in 100 ml of glucose yeast extract (GYE, glucose- 1.0%, yeast extract- 0.05%; pH- 7.0) broth contained in a 500 ml conical flask, under standard conditions i.e., at 30 o C, 130-150 rpm in an orbital shaker (Shaker incubator - New Brunswick Scientific Co., Inc., Edison, USA) for 24 h. The culture was centrifuged (10,000 g, 10 min, 4 o C) (High speed refrigerated centrifuge - Hitachi, Japan), and the cell free culture supernatant was mixed and agitated with equal volume of distilled chloroform (Thermo Fischer Scientific, USA) in a separating funnel (Borosil Glassworks, India). The chloroform layer was separated and concentrated on a rotary vacuum evaporator (35 o C /100 rpm, BUCHI, Switzerland). The solid brownish mass, left after the evaporation, was dissolved in chloroform in a concentration of 20 mg/ml and stored at -20 o C for further use.
Antimicrobial activity of B. gladioli OR1 against clinical isolates: The antimicrobial activity (AMA) of the chloroform extract of B. gladioli OR1 (CEBG) against clinical isolates of bacteria and fungi (obtained from Department of Microbiology, Government Medical College and Hospital, Chandigarh) was determined by Kirby-Bauer's disc-diffusion method  . The clinical isolates included 20 isolates of Staphylococcus aureus obtained from various sources like pus, semen, tissue cells, tracheal tip, umbilical tip and wound; 14 isolates of Pseudomonas aeruginosa from blood, pus, trachea, urine and wound; 11 of Acinetobacter CBC isolated from ascites fluid tap, blood, pus, sputum, trachea, tracheotomy pus, urine and wound; 11 Escherichia More Details coli isolates from catheter tip, pleural fluid, pus, sputum, trachea and urine; 6 Klebsiella pneumoniae isolates from urine and wound; 3 Citrobacter freundii isolates from urine; 3 Enterobacter species isolates from ascites fluid tap and blood; 1 Enterococcus species isolate from blood; 4 isolates each of Candida albicans and C. tropicalis from blood and urine. One hundred microlitres of ten-fold dilutions of actively growing (mid log phase) bacterial (both Gram-positive & Gram-negative) and yeast cultures (clinical isolates) having 0.5 McFarland turbidity were spread-plated uniformly (using a sterile glass spreader) onto NA and yeast extract peptone dextrose agar (YEPDA) (Hi-Media, Mumbai, India) plates, respectively. These plates were then allowed to dry in the laminar flow chamber for 5 min. Ten microlitres of the chloroform extract (conc.- 20 mg/ml) of B. gladioli OR1, was gently transferred to the sterile filter paper disks (6 mm diameter, Hi-Media, India) which were air dried for two min and then placed carefully onto cultured NA/YEPDA plates along with the pure chloroform-treated, dried disks as control. The plates were incubated for 24 h at 30 o C (for yeast) and 37 o C (for bacteria). The AMA was determined by measuring the diameter of the zone of inhibition of bacterial and fungal growth around the discs.
Association between B. gladioli OR1 growth and antimicrobial activity in GYE broth: A total of six flasks containing GYE broth inoculated with 1.0 per cent overnight grown B. gladioli OR1 culture, were incubated for different time intervals (24, 48 and 72 h), in duplicates under shaking conditions (130 rpm) at 30 o C. After each time interval, two flasks were withdrawn and the absorbance of the cultures measured at 600 nm using a UV/VIS spectrophotometer (Lab India UV 3000 + , India). The B. gladioli OR1 cultures were then centrifuged, the cell free supernatant pooled and the chloroform extract of the cell free supernatant was prepared and concentrated. The AMA of the chloroform extracts, obtained after each time interval were checked by Kirby-Bauer's disc-diffusion method using test microorganisms S. aureus (resistant to amikacin, ciprofloxacin, clindamycin, clinafloxacin, erythromycin, gentamicin and methicillin) and C. tropicalis (resistant to fluconazole and itraconazole).
Thin layer chromatography- Bioautography: The AMA of the chloroform soluble fraction of the supernatant of B. gladioli OR1 culture was qualitatively analyzed using Gibbons and Gray  TLC bioautography overlay assay. CEBG (20 μl) was spotted onto pre-coated silica gel 60 TLC strips (F 254, Merck Co, USA). The strips were developed in a solvent system [chloroform: methanol (9: 1)], air dried, examined under UV light (254 & 366 nm) and carefully laid over the solid medium (NA or YEPDA) plates. Finally, 20 ml of the soft agar media (agar conc.- 1.0%) containing 100 μl of actively growing cells (N=108 cells/ml) either of multi-drug resistant S. aureus or C. tropicalis, was gently laid over the developed TLC strips, placed on the surface of the respective medium plates, and incubated at 30 o C (for C. tropicalis) or 37 o C (for S. aureus) for 24 h. The R f values of the antimicrobial zones exhibited by the compounds, separated on the TLC strips were calculated.
Stability of antimicrobial compounds: The stability of antimicrobial compounds (AMCs) present in the cell free culture supernatant of B. gladioli OR1 [filtered through 0.22 μm PTFE membrane filter, 25 mm (Hangzhou Anow Microfiltration Co., Ltd., China)], towards heat and pH was determined.
Heat stability: Ten millilitres each of the cell free culture supernatant of B. gladioli OR1 were dispensed in various 50 ml screw capped conical flasks. The flasks were subjected to heat treatment (50, 70, 100 & 121 o C) for 20 min either in a water bath (up to 100 o C) or in an autoclave (121 o C).
pH stability: Ten millilitres each of cell free culture supernatant contained in different flasks were individually adjusted to various pH values (3.0, 5.0, 9.0, 11.0) using 0.1 M HCl or 0.1 M NaOH. Same amount of sterile distilled water was added to control samples. The samples were then kept at room temperature for one hour, chloroform extracted and assayed for AMA against multi-drug resistant S. aureus and C. tropicalis.
| Results & Discussion|| |
In the genus Burkholderia, mainly B. cepacia has been well documented to possess antimicrobial properties and some of these compounds have been characterized ,,,, . However, there are only a few reports on the antimicrobial nature of other species of Burkholderia including B. gladioli. Although a few studies have reported the antimicrobial activity of B. gladioli against plant pathogens belonging to the genera Alternaria, Aspergillus, Penicillium, Clavibacter, Listeria, Acidovorae, Acetobacter, Monilia, Botrytis and Rhodotorula,, , there is no report on the AMA of B. gladioli against clinical drug resistant pathogens of human origin. This observation, as well as the emergence of drug resistant microbial pathogens to currently used antibiotics led us to explore the antimicrobial profile of our isolate B. gladioli OR1 against clinical strains.
Microbial pathogens belonging to the genera Staphylococcus and Candida are posing serious health hazard, because of the isolation of multi-drug resistant strains from hospitals all over the world ,, . In the preliminary experiments (data not shown), a clear zone of inhibition around the B. gladioli OR1 colony patched in the centre of uniformly pre-streaked multi-drug resistant S. aureus and C. tropicalis plates indicated the ability of this organism to inhibit these drug resistant microbial isolates. Subsequent experiments proved that AMA was extracellular in nature and was chloroform soluble (data not shown). The chloroform extract of the cell free supernatant of B. gladioli OR1 was found to inhibit the growth of all the 20 clinical isolates of S. aureus tested. Of these 20, 10 isolates were sensitive to many antibiotics namely amikacin, amoxicillin-clavulanic acid, ciprofloxacin, clindamycin, clinafloxacin, erythromycin, gentamicin, linezolid, methicillin and vancomycin. The remaining 10 isolates of S. aureus were resistant to one or more antibiotics; four were resistant to a single antibiotic (clinafloxacin or gentamicin), two were resistant to two antibiotics (erythromycin and gentamicin), and four were multi-antibiotic resistant (amikacin, clinafloxacin and gentamicin; amikacin, ciprofloxacin, erythromycin and gentamicin; amikacin, ciprofloxacin, clindamycin, clinafloxacin, erythromycin, gentamicin and methicillin). The antimicrobial property of CEBG was confined not only to Staphylococci, but also to other bacterial pathogens namely, Acinetobacter, Enterococcus, Enterobacter and Citrobacter freundii [Table 1] isolated from various sites of human patients. However, CEBG did not inhibit the growth of E. coli, K. pneumoniae and P. aeruginosa. These results suggested that CEBG had a wide range of AMA against Gram positives but selective AMA against Gram negatives.
|Table 1: Anti-microbial activity of B. gladioli OR1 against clinical isolates|
Click here to view
Similarly, various species of drug resistant isolates of Candida, including C. albicans and C. tropicalis were inhibited by CEBG. Of the four isolates of C. tropicalis tested, one was sensitive to amphotericin B, fluconazole and itraconazole; one resistant to a single anti-fungal agent fluconazole and two were resistant to fluconazole and itraconazole. Of the three isolates of C. albicans inhibited by CEBG, one was sensitive to amphotericin B, fluconazole and itraconazole; two were resistant to single anti-fungal agent, either amphotericin B or fluconazole.
An association between B. gladioli OR1 growth and AMA was observed in GYE medium [Figure 1]. Although highest OD of 3.16 was observed after 48 h of incubation, but maximum AMA was observed during 'mid log phase' (OD=2.20) i.e., after 24 h of incubation and remained almost same thereafter, suggesting that very actively growing culture possessed maximal AMA. This observation was interesting because majority of microbes produce antibiotics (penicillin, streptomycin, gentamicin, cephalosporin, etc.) in their stationary phase rather than log phase of growth. Some bacteriocins  and an antibiotic, pyrrolnitrin  have also been earlier reported to be produced in the log phase.
|Figure 1: Growth and antimicrobial activity of B. gladioli OR1 (Growth conditions: GYE broth, pH-7.0, 30oC, 130 rpm, 1% inoculum. Values are mean ± SD of three individual experiments).|
Click here to view
The AMA of the cell free culture supernatant of B. gladioli OR1 was found to be highly heat stable as well as pH stable [Figure 2]. The anti-Candida activity was 100 per cent stable when the sample was heated up to 100 o C for 20 min but a small decrease of 1.4 per cent occurred in the autoclaved (121 o C for 20 min) sample. The anti-staphylococcal activity was 100 per cent heat stable up to 50°C, however, a decrease of 2.8, 8.4 and 13.9 per cent was observed when the samples were heated at 70, 100 and 121 o C, respectively. The production of heat stable antimicrobial compounds in the log phase of bacterial growth is not uncommon; some of the bacteriocins belonging to class II have been reported to be heat stable  . The AMA was quite stable in the pH range 3.0-11.0, with maximum stability observed at pH 7.0. Only a slight decrease in AMA was observed when the pH of the sample was adjusted to the acidic or alkaline values i.e., at 3.0, 5.0, 9.0 and 11.0, the sample retained 86.1-94.4 per cent of the anti-staphylococcal activity and 90.0-96.6 per cent of the anti-Candida activity. The pH and temperature data indicate that B. gladioli OR1 produces more than one AMC.
|Figure 2: Effect of temperature (a) and pH (b) on antimicrobial activity of the cell free supernatant of B. gladioli OR1. Values are mean ± SD of three individual experiments.|
Click here to view
The CEBG containing AMCs was subjected to silica gel TLC analysis in a solvent system comprising of chloroform: methanol 9: 1. The analysis of the separated compounds under UV light (254 and 365 nm) [and upon derivatizing the TLC with methanolic-sulphuric acid (10.0%)], revealed at least five major spots with R f values 0.24, 0.45, 0.59, 0.62 and 0.76. In order to find out the correlation of these spots with antimicrobial property, bioautography of the freshly developed air-dried TLC strips containing separated components of the extract was performed, using multi-drug resistant S. aureus and C. tropicalis as target organisms. The results [Figure 3] exhibited that B. gladioli OR1 produced at least three anti-staphylococcal compounds (R f values: 0.24, 0.45 & 0.59) and two anti-Candida compounds (R f values: 0.62 & 0.76).
|Figure 3: Bioautography exhibiting anti-S. aureus (a) and anti-C. tropicalis (b) activities of B. gladioli OR1.|
Click here to view
The present study emphasizes the importance of B. gladioli for the production of various AMCs which possess the potential to kill drug resistant pathogenic microbes. Once the compounds are purified and characterized, these can act as lead molecules in the design of novel microbial inhibitors.
| Acknowledgment|| |
The authors acknowledge the Department of Biotechnology, Government of India, New Delhi, for financial support and Dr (Mrs) Archana Singh, Panjab University, Chandigarh, for editing the manuscript.
| References|| |
|1.||Davies JC. Current and novel antimicrobial approaches. Prog Respir Res 2006; 34 : 180-6. |
|2.|| Singhi S, Deep A. Invasive candidiasis in pediatric intensive care units. Indian J Pediatr 2009; 76 : 1033-44. |
|3.|| Cheng M, Yang Y, Yao T, Lin C, Liu J, Tang R, et al. Risk factors for fatal candidemia caused by Candida albicans and non-albicans Candida species. BMC Infect Dis 2005; 5 : 22. |
|4.||Matouskova I, Janout V. Current knowledge of methicillin-resistant Staphylococcus aureus and community-associated methicillin-resistant S. aureus. Biomed Papers-Olomouc 2008; 152 : 191-202. |
|5.||Cowen LE, Anderson JB, Kohn LM. Evolution of drug resistance in Candida albicans. Ann Rev Microbiol 2002; 56 : 139-65. |
|6.||Cui L, Iwamoto A, Lian J, Neoh H, Maruyama T, Horikawa Y, et al. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50 : 428-38. |
|7.|| Nolte FS, Parkinson T, Falconer DJ, Dix S, Williams J, Gilmore C. Isolation and characterization of fluconazole- and amphotericin B- resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 1997; 44 : 196-9. |
|8.||Socha AM, LaPlante KL, Rowley DC. New bisanthraquinone antibiotics and semi-synthetic derivatives with potent activity against clinical Staphylococcus aureus and Enterococcus faecium isolates. Bioorg Med Chem 2006; 14 : 8446-54. |
|9.||Ligon JM, Hill DS, Hammer PE, Torkewitz NR, Hofmann D, Kempf H-J. Natural products with antifungal activity from Pseudomonas biocontrol bacteria. Nat Prod 2000; 56 : 688-95. |
|10.||Arguelles-Arias A, Ongena M, Halimi B, Brans A, Joris B, Fickers P, et al. Bacillus amyloliquefaciens GA1 as a source of potent antibiotics and other secondary metabolites for biocontrol of plant pathogens. Microb Cell Fact 2009; 8 : 63. |
|11.||Vandamme P, Holmes B, Vancanneyt M, Coenye T, Hoste B, Coopman R, et al. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int J Syst Bacteriol 1997; 47: 1188-200. |
|12.||Coenye T, Vandamme P, Govan J, Lipuma J. Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol 2001; 39 : 3427-36. |
|13.||Ghosh A, Paul D, Prakash D, Mayilraj S, Jain RK. Rhodococcus imtechensis sp. nov., a nitrophenol-degrading actinomycete. Int J Syst Evol Microbiol 2006; 56 : 1965-9. |
|14.||Bauer AW, Kirby WMM, Sheris JC, Turck M. Antibiotic susceptibility testing by a standardized single disc method. Am J Clin Pathol 1966; 45 : 493-6. |
|15.||Gibbons S, Gray AI. Isolation by Planar Chromatography. In: Cannell RJP, editor. Natural products isolation, 1 st ed. Totowa, New Jersey: Humana Press Inc; 1998. p. 209-45. |
|16.||Lim Y, Suh J-W, Kim S, Hyun B, Kim C, Lee C. Cepacidine A, a novel antifungal antibiotic produced by Pseudomonas cepacia. II. Physicochemical properties and structure elucidation. J Antibiot 1994; 47 : 1406-16. |
|17.||Jiao Y, Yoshihara T, Ishikuri S, Uchino H, Ichihara A. Structural identification of cepaciamide A, a novel fungitoxic compound from Pseudomonas cepacia D-202. Tetrahedron Lett 1996; 37 : 1039-42. |
|18.||Moon S, Kang PM, Park KS, Kim CH. Plant growth promoting and fungicidal 4-quinolinones from Pseudomonas cepacia. Phytochemistry 1996; 42 : 365-8. |
|19.||Mao S, Lee S, Hwangbo H, Kim Y, Park K, Cha G, et al. Isolation and characterization of antifungal substances from Burkholderia species culture broth. Curr Microbiol 2006; 53 : 358-64. |
|20.||Sultan Z, Park K, Lee SY, Park JK, Varughese T, Moon SS. Novel oxidized derivatives of antifungal pyrrolnitrin from the bacterium Burkholderia cepacia K87. J Antibiot 2008; 61 : 420-5. |
|21.||Altindag M, Sahin M, Esitken A, Ercisli S, Guleryuz M, Donmez MF, et al. Biological control of brown rot (Moniliana laxa Ehr.) on apricot (Prunus armeniaca L. cv. Hacihaliloglu) by Bacillus, Burkholderia and Pseudomonas application under in vitro and in vivo conditions. Biol Control 2006; 38 : 369-72. |
|22.||Hu F, Young JM. Biocidal activity in plant pathogenic Acidovorax, Burkholderia, Herbaspirillum, Ralstonia, and Xanthomonas sp. J Appl Microbiol 1998; 84 : 263-71. |
|23.||Segonds C, Clavel-Batut P, Thouverez M, Grenet D, Coustumier AL, Plesiat P, et al. Microbiological and epidemiological features of clinical respiratory isolates of Burkholderia gladioli. J Clin Microbiol 2009; 47 : 1510-6. |
|24.||Livermore DM. Antibiotic resistance in Staphylococci. Int J Antimicrob Agents 2000; 16 : 3-10. |
|25.||Al-Tatari H, Abdel-Haq N, Chearskul P, Asmar B. Antibiotics for treatment of resistant Gram-positive coccal infections. Indian J Pediatr 2006; 73 : 323-34. |
|26.||Ruan S, Ren-Hsueh P. Invasive candidiasis: An overview from Taiwan. J Formos Med Assoc 2009; 108 : 443-51. |
|27.||Drider D, Fimland G, Héchard Y, McMullen LM, Prévost H. The continuing story of class IIa bacteriocins. Microbiol Mol Biol 2006; 70 : 564-82. |
|28.||El-Banna N, Winkelmann G. Pyrrolnitrin from Burkholderia cepacia: antibiotic activity against fungi and novel activities against Streptomycetes. J Appl Microbiol 1998; 85 : 69-78. |
[Figure 1], [Figure 2], [Figure 3]